

Press Release

OTOFARMA: CLOSING COMPLETED FOR THE NEW FACILITY IN MILAN

Final property purchase agreement signed: strategic €1.5 million transaction completed

Naples, 22 April 2026 – The Otofarma Group – with over 30 years' experience in the hearing care sector and a leader in the manufacture of hearing aids distributed primarily through the pharmaceutical channel – announces that it has signed the final sale and purchase agreement for the acquisition of the **new production plant in Corsico**, in the Milan metropolitan area, thereby completing the closing of the transaction previously announced in recent months.

The property officially becomes part of the Group's assets, marking a key milestone in Otofarma's industrial growth.

The **total investment of €1,500,000** will enable the company to double its production capacity, further strengthening Otofarma's position as one of the leading players in the manufacture of hearing aids in Italy.

The new site, covering an area of approximately **3,000 square metres**, will be dedicated primarily to the production of Otofarma-branded devices and will be equipped with state-of-the-art technology for the manufacture of customised hearing aids. The expansion will enable a significant increase in production volumes and an improvement in operational efficiency.

This move is in response to the growing demand seen in recent years, driven both by the increase in the number of hearing-impaired patients and by the success of the distribution model based on a network of **4,462 affiliated pharmacies (as at 31 December 2025)**.

Thanks to its location in a strategic area of its target market, the new facility will also enable shorter delivery times, greater customisation of devices and enhanced flexibility across the entire supply chain.

The Corsico site will not replace existing facilities, but will complement and strengthen their activities, supporting continuous growth without impacting current production. **The sales and marketing offices are expected to open by 2027, whilst the first production lines are expected to become operational by 2028.**

*"The completion of the transaction marks a crucial step in our industrial development plan," said **Gennaro Bartolomucci, CEO of Otofarma**. "With the new plant in Corsico, we are consolidating our presence in our main target market and laying even stronger foundations for sustained, innovative and long-term growth."*

With the completion of the transaction, Otofarma reaffirms its strategy focused on innovation and the strengthening of an entirely Italian production model, capable of combining advanced technology, accessibility and proximity to the patient.

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by [CONSOB](#) by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website www.otofarmaspa.com.

Identification Codes

Alphanumeric Code: OTO

ISIN for Ordinary Shares: IT0005663361

About Otofarma SpA

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, Chairman and CEO, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

For more information:

Otofarma S.p.A.- Investor relations

Anna Incarnato Bartolomucci

E-mail: investor.relations@otofarma.it

mob: +39 347 0506780

Alantra – Euronext Growth Advisor

E-mail: ega@alantra.com

mob: +39 334 6267242

SEC Newgate – Media Relations

+39 02 624 999 1

Michele Bon – michele.bon@secnewgate.it – +39 338 693 3868

Francesca Brambilla – francesca.brambilla@secnewgate.it – +39 338 627 2146